Jurriaan E.M. de Steenwinkel

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Jeroen J. A. van Kampen, David van de Vijver, Pieter L. A. Fraaij et al. · Nature Communications · 2021 · 843 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants

Jeroen J. A. van Kampen, David van de Vijver, Pieter L. A. Fraaij et al. · medRxiv · 2020 · 255 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis

Jurriaan E.M. de Steenwinkel, Gerjo J. de Knegt, M. T. ten Kate et al. · Journal of Antimicrobial Chemotherapy · 2010 · 165 citations

Medicine, Pharmacology, Pharmacotherapy +15

Drug Susceptibility of<i>Mycobacterium tuberculosis</i>Beijing Genotype and Association with MDR TB

Jurriaan E.M. de Steenwinkel, Marian T. ten Kate, Gerjo J. de Knegt et al. · Emerging infectious diseases · 2012 · 95 citations · Full text

Medicine, Pharmacology, Pharmacogenetics +13

Optimization of the Rifampin Dosage to Improve the Therapeutic Efficacy in Tuberculosis Treatment Using a Murine Model

Jurriaan E.M. de Steenwinkel, Rob E. Aarnoutse, Gerjo J. de Knegt et al. · American Journal of Respiratory and Critical Care Medicine · 2013 · 94 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9